We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
- Authors
Dormandy, John A; Charbonnel, Bernard; Eckland, David J A; Erdmann, Erland; Massi-Benedetti, Massimo; Moules, Ian K; Skene, Allan M; Tan, Meng H; Lefèbvre, Pierre J; Murray, Gordon D; Standl, Eberhard; Wilcox, Robert G; Wilhelmsen, Lars; Betteridge, John; Birkeland, Kåre; Golay, Alain; Heine, Robert J; Korányi, László; Laakso, Markku; Mokán, Marián; Norkus, Antanas; Pirags, Valdis; Podar, Toomas; Scheen, André; Scherbaum, Werner; Schernthaner, Guntram; Schmitz, Ole; Skrha, Jan; Smith, Ulf; Taton, Jan; PROactive Investigators
- Abstract
Patients with type 2 diabetes are at high risk of fatal and non-fatal myocardial infarction and stroke. There is indirect evidence that agonists of peroxisome proliferator-activated receptor gamma (PPAR gamma) could reduce macrovascular complications. Our aim, therefore, was to ascertain whether pioglitazone reduces macrovascular morbidity and mortality in high-risk patients with type 2 diabetes.
- Publication
Lancet (London, England), 2005, Vol 366, Issue 9493, p1279
- ISSN
1474-547X
- Publication type
Journal Article
- DOI
10.1016/S0140-6736(05)67528-9